Clinical trial
INST 0601C: A Non-Randomized Phase II Protocol of Erlotinib for Patients With Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
NCT00391586 is registered in ClinicalTrials.gov with New Mexico Cancer Research Alliance as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- INST 0601C: A Non-Randomized Phase II Protocol of Erlotinib for Patients With Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
- Lead sponsor
- New Mexico Cancer Research Alliance
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- July 31, 2006
- Completion date
- May 31, 2012
- Enrollment
- 45 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.